Table I.

Time until redosing in days after different doses and routes of administration of canakinumab

Patient 10 mg/kg i.v. 1 mg/kg i.v. First 150 mg s.c. Second 150 mg s.c. Third 150 mg s.c. Fourth 150 mg s.c. Fifth 150 mg s.c. Sixth 150 mg s.c. 
1 168 90 120 119 112 133 113a n.a. 
2 189 91 98 133 126 132 90a n.a. 
3 203 77 133 140 132 134a n.a. n.a. 
4 182 98 118 141 132 127a n.a. n.a. 
5 n.a. n.a. 187 156 161a n.a. n.a. n.a. 
6 n.a. n.a. 91 84 98 78 55 85 
7 n.a. n.a. 168 230a n.a. n.a. n.a. n.a. 
Patient 10 mg/kg i.v. 1 mg/kg i.v. First 150 mg s.c. Second 150 mg s.c. Third 150 mg s.c. Fourth 150 mg s.c. Fifth 150 mg s.c. Sixth 150 mg s.c. 
1 168 90 120 119 112 133 113a n.a. 
2 189 91 98 133 126 132 90a n.a. 
3 203 77 133 140 132 134a n.a. n.a. 
4 182 98 118 141 132 127a n.a. n.a. 
5 n.a. n.a. 187 156 161a n.a. n.a. n.a. 
6 n.a. n.a. 91 84 98 78 55 85 
7 n.a. n.a. 168 230a n.a. n.a. n.a. n.a. 

Patients 1–4 were initially treated with 10 mg/kg and 1 mg/kg i.v. and subsequently with fixed doses of 150 mg s.c. Patients 5–7 did not receive i.v. dosing but received fixed doses of 150 mg s.c. Because of difficulties being compliant with study visit requests, patient 6 withdrew consent after the sixth dose of 150 mg canakinumab s.c. The patient was subsequently treated with anakinra. n.a., not applicable.

a

After this cycle, patients were rolled over into the subsequent study, in which they were treated with a fixed dosing regimen of 150 mg s.c. every 8 wk.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept